Breye Therapeutics raises €67.5 million in…

COPENHAGEN, Denmark, Sept. 29, 2026 -- Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announced the successful close of an over-subscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital. The proceeds of the financing will be used to advance Breye’s lead asset danegaptide into a randomized Phase 2 clinical trial in patients with NPDR. The study, which will aim to demonstrate clinical proof-of-concept, is due to start in 2027.